Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.